A first-in-kind MAPK13 inhibitor corrects stem cell reprogramming and muco-obstructive lung disease
- Open access
- 2 cites
The AI brief for this paper is being written. Open it in JClub to read the paper with the brief as soon as it lands.
Read the brief in JClub →